# Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

> **NCT06923072** · PHASE2 · RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 12 (estimated)

## Conditions studied

- Kohlmeier-Degos Disease
- Malignant Atrophic Papulosis
- Degos Disease
- Papulosis, Malignant Atrophic

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT06923072
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-18
- **Primary completion:** 2030-12-14
- **Final completion:** 2030-12-15
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06923072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06923072, "Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06923072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*